Video
Mesalazine: Oral, rectal or both?
Video report presented by Professor Dr. Wolfgang Kruis, Ev. Krankenhaus Kalk, Cologne, Germany, at the Symposium 205 “New Treatment Targets in Gut and Liver Diseases”, October 21 – 22, 2016 in Lucerne, Switzerland.
© Falk Foundation e.V., Freiburg. All rights reserved.
Summary
A symposium sponsored by the Falk Foundation entitled “New Treatment Targets in Gut and Liver Diseases” was held in October 2016. Important findings with regard to optimized use of proven therapeutic options in chronic inflammatory bowel diseases were a main topic. Professor Dr. Wolfgang Kruis from Cologne spoke about the importance of mesalazine in ulcerative colitis. Mesalazine has been the standard therapy in ulcerative colitis for decades. The active substance demonstrates a local anti-inflammatory efficacy. However, the treatment opportunities provided by an oral plus rectal administration of mesalazine are not optimally exploited up to now. Particularly in distal disease, rectal treatment where appropritate in combination with oral administration of mesalazine is indicated in order to ensure optimal therapeutic success. Rectal formulations ensure sufficiently high concentrations of the active substance in the different segments of the colon descendens. Clinical symptoms of ulcerative colitis are mainly the result of inflammatory activity in this section of the colon. The entire colon can be reached with the combination of oral and rectal mesalazine, so that even extensive ulcerative colitis can easily be treated in an anti-inflammatory manner. Clinical trial results confirm that the combined oral and rectal administration of mesalazine shows an increased clinical efficacy in extensive ulcerative colitis. The remission rate was increased and there was a significant clinical improvement after 4 and after 8 weeks of additional rectal administration of mesalazine. Standard therapy of ulcerative colitis with mesalazine can be further optimized. The additional benefit of a combined oral and rectal mesalazine administration is not fully exploited up to now. Patients can benefit from a combined oral and rectal administration of mesalazine. Clinical trial results show an increased remission rate and a significant clinical improvement under this combined treatment.
Please switch on your loudspeakers!
Link to Falk Mediacenter
Latest research in brief:
Bowel
Text:
Blixt T et al, Gastroenterology. 2017;152(5):1031–41.e2
Clostridium difficile infection: TAsymptomatic carriers of toxigenic C. difficile strains in hospitals increase the risk of infection in other patients.
Link to text
Text:
Jørgensen KK et al, Lancet. 2017; 389(10086):2304–16
Switchting from infliximab originator to a biosimilar – the NOR-SWITCH trial: Switching to CT-P13 in patients with chronic inflammatory diseases was not inferior to continued treatment with infliximab originator according to a prespecified non-inferiority margin of 15%.
Link to text
Text:
Lindsay JO et al, Lancet Gastroenterol Hepatol. 2017;2(6):399–406
Efficacy of autologous hematopoietic stem-cell transplantation (HSCT) in treatment-refractory Crohn’s disease: Pooled data of all patients enrolled in ASTIC, which underwent HSCT, revealed that 38% of patients achieve steroid-free clinical remission after 1 year, while half of the patients achieve endoscopic remission. However, infectious complications are common.
Link to text
Liver Biliary Tracts
Text:
Chen G et al, Hepatology. 2017;66(1):13–26
Belperio PS et al, Hepatology. 2017;66(1):27–36
Hepatitis B reactivation during oral hepatitis C treatment: Two current retrospective analyses demonstrate that hepatitis B reactivation can occur even in occult hepatitis B virus infection (HBsAg-negative, HBV DNA-positive) and in patients with positive anti-HBc only. In contrast to interferon-based therapy, HBV reactivation occurs early during treatment; severe biochemical hepatitis, however, is very rare.
Link to text
Text:
Sinha R et al, J Hepatol. 2017;67(1):40–46
Liver cirrhosis: Long-term treatment with carvedilol as portal hypotensive agent is associated with improved survival in patients with mild ascites. In patients with moderate or severe ascites, carvedilol does not increase mortality.
Link to text
Text:
Sapisochin G et al, J Hepatol. 2017;67(1):92–99
Hepatocellular carcinoma (HCC): Stereotactic body radiotherapy (SBRT) can be safely utilized as a bridge to liver transplant in patients with HCC. 1-, 3- and 5-year survival after listing or transplant were comparable with SBRT versus transarterial chemoembolization or radiofrequency ablation as bridging therapy. Thus, SBRT is a useful alternative to conventional bridging therapies.
Link to text
Oesophagus Stomach Duodenum
Text:
Abraham NS et al, Gastroenterology. 2017;152(5):1014–22.e1
Risk of gastrointestinal bleeding during therapy with direct oral anticoagulants: Population-based retrospective study revealed that the safety profile of apixaban is superior to dabigatran or rivaroxaban. In patients aged 75 years or older, bleeding risk increases with age.
Link to text
Text:
Kudo T et al, Lancet Oncol. 2017;18(5):631–9
Immunotherapy of patients with refractoy esophageal squamous-cell carcinoma: Proof of concept study with Nivolumab reveals objective response in 17% of patients with a manageable safety profile.
Link to text
Text:
Mukewar SS et al, Am J Gastroenterol. 2017;112(6):959–67
Therapy of refractory celiac disease: “Open-capsule” budesonide induces clinical and histopathologic improvement in a majority of patients.
Link to text
Pancreas
Text:
Buxbaum JL et al, Am J Gastroenterol. 2017;112(5):797–803
Hydration therapy in acute pancreatitis: Randomized trial confirms that early aggressive intravenous hydration with Lactated Ringer’s solution hastens clinical improvement in patients with mild acute pancreatitis.
Link to text
International Symposia and Workshops
Symposium 208
IX GASTRO-CONFERENCE (Part I)
Eosinophilic Esophagitis – Medical and Dietary Treatment
October 4 – 5, 2017, Berlin, Germany
Maritim Hotel Berlin, Stauffenbergstr. 26, 10785 Berlin, Germany
Registration
Online registration
Symposium 209
IX GASTRO-CONFERENCE (Part II)
IBD 2017 – Therapeutic and Biological Barriers
October 6 – 7, 2017, Berlin, Germany
Maritim Hotel Berlin, Stauffenbergstr. 26, 10785 Berlin, Germany
Registration
Online registration
Current Falk literature:
Mucofalk®
Nature’s recipe for good digestion
Hemorrhoids and hemorrhoidal disease
(16 pages)
M90e
Picture:
http://newsletter.drfalkpharma.de/FGI_8-9-17/M90e_1-5-17.jpg
PDF download